Respiratory syncytial virus nosocomial outbreak in neonatal intensive care: A review of the incidence, management, and outcomes
| Autor: | Sarah Alqarni, Shahad T. Alsaidi, Afnan S. Bawakid, Rafat Mosalli, Bosco Paes, Wed Khayyat, Amirah S. Almatrafi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Palivizumab
medicine.medical_specialty Neonatal intensive care unit Epidemiology Respiratory Syncytial Virus Infections Cochrane Library Antiviral Agents Disease Outbreaks Intensive care Intensive Care Units Neonatal medicine Infection control Humans Prospective Studies Cross Infection business.industry Health Policy Incidence (epidemiology) Incidence Public Health Environmental and Occupational Health Infant Newborn Outbreak Infant Respiratory Syncytial Viruses Infectious Diseases Systematic review Emergency medicine Intensive Care Neonatal business medicine.drug Systematic Reviews as Topic |
| Zdroj: | American journal of infection control. 50(7) |
| ISSN: | 1527-3296 |
| Popis: | Background : The main objective was to determine the incidence, management, and outcomes of respiratory syncytial virus nosocomial infection (RSVNI) outbreaks in neonatal intensive care units (NICU). Methods : A comprehensive search of RSVNI in 9 databases was conducted from January 1st 2000 to May 1st 2021, of which the Cochrane Library comprised the Cochrane central register of controlled trials and the Cochrane database of systematic reviews. Two hundred and twenty-eight articles were retrieved and 17 were retained. A descriptive analysis was performed, and frequencies are reported as mean, median, and range where pertinent. Results : One hundred and seventeen infants were analyzed and comprised preterms (88.1%) and those with pre-existing co-morbidities. The estimated proportional incidence of RSVNI was 23.8% (177/744) infants. Outbreaks were principally managed by conventional protective measures, NICU closure, and visitor restriction. Palivizumab was used to control RSVNI in 10 studies. RSVNI-related mortality was 8.5% (15/177) and 8.0% (7/87) among infants where infection control was solely employed. Conclusion : RSVNI is associated with significant morbidity and mortality. The use of palivizumab should be a multidisciplinary decision, based on rapidly spreading infection. Prospective studies are essential to determine the cost-benefit of palivizumab versus standard prevention control for an RSVNI outbreak. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect